This Week at FDA: FDA’s ad crackdown, abandoning adcomms, and more

This Week at FDAThis Week at FDABiologics/ biosimilars/ vaccinesGovernment/legislationGuidanceLeadershipMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)